

February 19, 2003

Public Relations

Ono Pharmaceutical Co., Ltd.

Tel: +81-6-6222-5551

Fax: +81-6-6222-2875

### **Announcement of Discontinuation of ONO-5816 Clinical Study for Diabetes**

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, President: Kimiichiro Matsumoto) announced today that the Japanese Phase IIa clinical study of ONO-5816 as an agent for the treatment of diabetes has been discontinued. The discontinuation was decided after new data from an animal study was obtained.

ONO-5816 increases sensitivity to insulin to lower blood glucose levels without activating insulin secretion. In June 2002, Ono commenced a clinical study in patients with Type II diabetes.

However, a 12-month toxicity study in monkeys revealed histopathological changes which were not observed in an earlier 9-month toxicity study performed in the same species prior to the clinical study. Ono determined that it would be in the best interest of the patients to halt the clinical study, taking into consideration the results of the 12-month toxicity study in monkeys.